Evidence map›Paper›PMID 24899204›Full record

ArticleJournal of virology2014

Limited dissemination and shedding of the UL128 complex-intact, UL/b'-defective rhesus cytomegalovirus strain 180.92.

Basel T Assaf, Keith G Mansfield, Lisa Strelow, Susan V Westmoreland, Peter A Barry, Amitinder Kaur

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Basel T AssafDivision of Comparative Pathology, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA Center for Comparative Medicine, University of California, Davis, Davis, California, USA.
Keith G MansfieldDivision of Comparative Pathology, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA.
Lisa StrelowCenter for Comparative Medicine, University of California, Davis, Davis, California, USA.
Susan V WestmorelandDivision of Comparative Pathology, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA.
Peter A BarryCenter for Comparative Medicine, University of California, Davis, Davis, California, USA Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, California, USA California National Primate Research Center, University of California, Davis, Davis, California, USA.
Amitinder KaurDivision of Immunology, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA amitinder_kaur@hms.harvard.edu.
University of California, Davis · USHarvard University · USNew England Biolabs (United States) · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10R01AI049342 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, WALTER, MARK R · 2002 to 2017
$6.9M
INTERACTIONS BETWEEN CMV AND SIV IN RHESUS MACAQUESR01AI043890 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI KAUR, AMITINDER · 1998 to 2007
$2.4M
Research Training in Veterinary & Comparative PathologyT32OD011064 · OD · HARVARD MEDICAL SCHOOL · PI SPEALMAN, ROGER D · 2012 to 2014
$694k
NIAID NIH HHS R01 AI043890NIAID NIH HHS R01 AI049342NIAID NIH HHS R01 AI43890NIAID NIH HHS R01 AI49342NIH HHS P51 OD011107NIH HHS P51 OD0111103NIH HHS T32 OD011064
6 · The paper itself

Abstract

unlabelledThe UL128 complex of human cytomegalovirus (CMV) is a major determinant of viral entry into epithelial and endothelial cells and a target for vaccine development. The UL/b' region of rhesus CMV contains several open reading frames, including orthologs of the UL128 complex. We recently showed that the coding content of the rhesus CMV (RhCMV) UL/b' region predicts acute endothelial tropism and long-term shedding in vivo in the rhesus macaque model of CMV infection. The laboratory-passaged RhCMV 180.92 strain has a truncated UL/b' region but an intact UL128 complex. To investigate whether the presence of the UL128 complex alone was sufficient to confer endothelial and epithelial tropism in vivo, we investigated tissue dissemination and viral excretion following experimental RhCMV 180.92 inoculation of RhCMV-seronegative rhesus macaques. We show the presence of at least two virus variants in the RhCMV 180.92 infectious virus stock. A rare variant noted for a nontruncated wild-type-virus-like UL/b' region, rapidly emerged during in vivo replication and showed high-level replication in blood and tissues and excretion in urine and saliva, features similar to those previously reported in naturally occurring wild-type RhCMV infection. In contrast, the predominant truncated version of RhCMV 180.92 showed significantly lower plasma DNAemia and limited tissue dissemination and viral shedding. These data demonstrate that the truncated RhCMV 180.92 variant is attenuated in vivo and suggest that additional UL/b' genes, besides the UL128 complex, are required for optimal in vivo CMV replication and dissemination. IMPORTANCE: An effective vaccine against human CMV infection will need to target genes that are essential for virus propagation and transmission. The human CMV UL128 complex represents one such candidate antigen since it is essential for endothelial and epithelial cell tropism, and is a target for neutralizing antibodies in CMV-infected individuals. In this study, we used the rhesus macaque animal model of CMV infection to investigate the in vivo function of the UL128 complex. Using experimental infection of rhesus macaques with a rhesus CMV virus variant that contained an intact UL128 complex but was missing several other genes, we show that the presence of the UL128 complex alone is not sufficient for widespread tissue dissemination and virus excretion. These data highlight the importance of in vivo studies in evaluating human CMV gene function and suggest that additional UL/b' genes are required for optimal CMV dissemination and transmission.

Indexed as

AnimalsCell LineCytomegalovirusCytomegalovirus InfectionsDisease Models, AnimalEndotheliumEpitheliumFibroblastsHumansMacaca mulattaMembrane GlycoproteinsOpen Reading FramesViral Envelope ProteinsViral ProteinsViral TropismVirus ReplicationMembrane GlycoproteinsUL128 protein, human cytomegalovirusViral Envelope ProteinsViral Proteins

Identifiers

PMID24899204
PMCPMC4136270
OpenAlexW2121616811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.